LBA39 3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus xevinapant or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck
Jean Bourhis(University of Lausanne), Yunxia Tao(Huanghuai University), P. Boisselier(Institut de Recherche en Cancérologie de Montpellier), Y. Pointreau(Centre Hospitalier Universitaire de Nantes), Xinghua Sun(L'Hôpital Nord Franche-Comté), C. Le Tourneau(Université de Versailles Saint-Quentin-en-Yvelines), Clément Sire(Centre National de la Recherche Scientifique), Kathrin Gollmer(Debiopharm (Switzerland)), M. Alfonsi(Centre Hospitalier Universitaire de Nantes), Sergio Szyldergemajn(Debiopharm (Switzerland)), J. Biau(Centre Jean Perrin), Florian Clatot, M-C. Kaminsky-Forrett(Institut de Cancérologie de Lorraine), L. Martin(Groupe Hospitalier du Havre), J.P. Delord(Institut universitaire du cancer de Toulouse Oncopole), Alexandre Coutté, F. Rolland(Institut de Cancérologie de l'Ouest), C. Even(Institut Gustave Roussy)
Cited by 7
Related Papers
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
|Head & Neck|2005|1.8k
Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02
|Journal of Clinical Oncology|2010|806
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
|Journal of Clinical Oncology|2005|491
Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study
|Journal of Clinical Oncology|2013|418